Merck (NYSE:MRK) Reports Strong Phase 3 Results For WINREVAIR In PAH Treatment

Yahoo Finance13:31 ET

Citi Maintains Merck & Co(MRK.US) With Buy Rating

Moomoo News12:31 ET · Ratings

Merck Highlights Phase 3 ZENITH Trial Evaluating WINREVAIR; Says Trial Stopped Early Due To 'Overwhelming Efficacy Demonstrated in the Primary Endpoint'

BenzingaMar 31 10:08 ET

Express News | Merck & Co Inc - Winrevair Reduces Major Morbidity and Mortality in High-Risk Pah Patients

ReutersMar 31 10:00 ET

Express News | Merck & Co Inc - Winrevair Safety Profile Consistent With Previous Studies

ReutersMar 31 10:00 ET

Express News | Winrevair™ (Sotatercept-Csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (Pah) by 76% Compared to Placebo in the Phase 3 Zenith Trial

ReutersMar 31 10:00 ET